Added to YB: 2025-12-18
Pitch date: 2025-11-14
VKTX [bullish]
Viking Therapeutics, Inc.
-9.9%
current return
Author Info
Alpha Talon Investment Research is a Hong Kong–based private family office deploying only proprietary capital across biotech, value turnarounds, and catalyst-driven shorts, focused on intrinsic value, regulatory odds, and mispriced fundamentals. Sign up for the newsletter.
Company Info
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
Market Cap
$4.1B
Pitch Price
$38.07
Price Target
110.00 (+208%)
Dividend
N/A
EV/EBITDA
-12.29
P/E
-17.06
EV/Sales
N/A
Sector
Biotechnology
Category
growth
From Pipeline to Platform: Viking Therapeutics's (NASDAQ: VKTX) Metabolic Inflection Point
VKTX: Clinical-stage biotech with dual GLP-1/GIP agonist VK2735 (injectable + oral) showing ~14-15% weight loss in 13wks, Phase 3 trials ongoing. Also developing VK2809 for NASH with 55% liver-fat reduction. $715M cash, zero debt funds through 2027. Base case $110 PT (~190% upside). M&A probability 55-60% as Amgen/AstraZeneca eye scarce oral GLP-1 assets.
Read full article (17 min)